{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:28:48Z","timestamp":1790702928187,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016292","name":"National Applied Research Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jid.2023.04.009","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T20:36:51Z","timestamp":1682627811000},"page":"2211-2218.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment \u2013 a Nationwide Cohort Study"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-023X","authenticated-orcid":false,"given":"David","family":"Thein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-3546","authenticated-orcid":false,"given":"Nana A.L.","family":"Rosen\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-1545","authenticated-orcid":false,"given":"Julia-Tatjana","family":"Maul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-1892","authenticated-orcid":false,"given":"Jashin J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9680","authenticated-orcid":false,"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0016-6791","authenticated-orcid":false,"given":"Lars Erik","family":"Bryld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9792-7305","authenticated-orcid":false,"given":"Mads K.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9620-875X","authenticated-orcid":false,"given":"Kawa Khaled","family":"Ajgeiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-300X","authenticated-orcid":false,"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3770-1743","authenticated-orcid":false,"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8257-1816","authenticated-orcid":false,"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2023.04.009_bib1","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/jdv.16180","article-title":"Real-world evidence of secukinumab in psoriasis treatment \u2013 a meta-analysis of 43 studies","volume":"34","author":"Augustin","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2023.04.009_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2023.04.009_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033486","article-title":"Off-label biologic regimens in psoriasis: A systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy","volume":"7","author":"Brezinski","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2023.04.009_bib4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaad.2019.03.048","article-title":"Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis","volume":"81","author":"Egeberg","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2023.04.009_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2023.04.009_bib6","first-page":"201","article-title":"Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis","volume":"21","author":"Feldman","year":"2015","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jid.2023.04.009_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjd.13343","article-title":"Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris","volume":"172","author":"Gniadecki","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2023.04.009_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2023.04.009_bib9","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2023.04.009_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jid.2017.09.044","article-title":"Differential drug survival of second-line biologic therapies in patients with psoriasis: observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"138","author":"Iskandar","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.04.009_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34293-y","article-title":"Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence","volume":"8","author":"Lin","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2023.04.009_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14808","article-title":"Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis Registry","volume":"34","author":"Lockshin","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2023.04.009_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/ijd.14429","article-title":"Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis","volume":"58","author":"Lunder","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2023.04.009_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdin.2021.05.003","article-title":"Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study","volume":"4","author":"Lytvyn","year":"2021","journal-title":"JAAD Int"},{"key":"10.1016\/j.jid.2023.04.009_bib15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(19)31772-6","article-title":"Psoriasis biologics: a new era of choice","volume":"394","author":"Mahil","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2023.04.009_bib16","first-page":"1067","article-title":"Biologic drug survival in psoriasis: A systematic review & comparative meta-analysis","volume":"0","author":"Mourad","year":"2021","journal-title":"Front. Med. Frontiers"},{"key":"10.1016\/j.jid.2023.04.009_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.01.029","article-title":"Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study [e-pub ahead of print]","author":"Nielsen","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2023.04.009_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/09546634.2012.751483","article-title":"Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients\u00a0with\u00a0psoriasis in daily practice","volume":"24","author":"Reek","year":"2013","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2023.04.009_bib19","article-title":"Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice","volume":"34","author":"Ruiz-Villaverde","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2023.04.009_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaad.2019.02.031","article-title":"Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study","volume":"81","author":"Torres","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2023.04.009_bib21","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: A retrospective multi-country, multicentric cohort study","volume":"22","author":"Torres","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2023.04.009_bib22","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: A prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"135","author":"Warren","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.04.009_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/09546634.2016.1247946","article-title":"Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study","volume":"28","author":"Wu","year":"2017","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2023.04.009_bib24","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2023.04.009_bib25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjd.18981","article-title":"Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"183","author":"Yiu","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23020419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23020419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:53:31Z","timestamp":1762206811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23020419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0022202X23020419"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2023.04.009","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment \u2013 a Nationwide Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2023.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}